Posted by Michael Wonder on 31 May 2023
Schedule of Pharmaceutical Benefits - 1 June 2023
1 June 2023 - The June 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The June issue of the Schedule includes a few major new/revised listings:
- Apalutamide (Eryland) - new indication
- Cannabidiol (Epidyolex) - new indication
- Cyclosporin (Cequa) - new formulation
- Lenvatinib mesylate (Lenvima) - new indication
- Pembrolizumab (Keytruda) - new indication
- Selinexor (Xpovio) - new indication
